Lindsay Renfro, PhD
Associate Professor of Research Population and Public Health Sciences; Children’s Oncology Group Associate Group Statistician
Dr. Lindsay Renfro is an Associate Professor of Research at the University of Southern California and the Associate Group Statistician for Children's Oncology Group (COG). COG is the pediatric cooperative group member of the NIH/NCI's National Clinical Trials Network and the world's largest organization dedicated exclusively to pediatric cancer research. Within COG, Dr. Renfro is also a faculty statistician for the Renal Tumors Committee, where she leads the design and analysis of therapeutic and biology-driven clinical trials for Wilms Tumor and related projects in pediatric renal cancer. Her expertise and methodological interests also include novel trial designs (e.g., adaptive, Bayesian, biomarker-driven, and master protocols), evaluation and validation of surrogate endpoints in clinical trials, and construction, validation, and implementation of disease-specific prognostic calculators for clinical use and decision-making. Dr. Renfro also enjoys teaching statistics to non-statisticians, mentoring students, traveling, and enjoying the mountains and beaches of Southern California with her son, Will.
Authors' Reply to the Letter to the Editor by Daniel M. Green.
J Natl Compr Canc Netw. 2022 Mar;20(3):xlvii-xlviii. doi: 10.6004/jnccn.2022.7002. PubMed PMID: 35276672;
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
J Clin Oncol. 2022 May 17;:JCO2200098. doi: 10.1200/JCO.22.00098. Epub 2022 May 17. PubMed PMID: 35580298;
Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
Cell Rep Med. 2022 Jun 21;3(6):100644. doi: 10.1016/j.xcrm.2022.100644. Epub 2022 May 25. PubMed PMID: 35617957; PubMed Central PMCID: PMC9244995.
Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
Biometrics. 2021 Aug 20;. doi: 10.1111/biom.13550. Epub 2021 Aug 20. PubMed PMID: 34415052; PubMed Central PMCID: PMC8858338.
Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
J Natl Compr Canc Netw. 2021 Aug 1;19(8):978-985. doi: 10.6004/jnccn.2021.7070. Epub 2021 Aug 1. PubMed PMID: 34416705; PubMed Central PMCID: PMC8805512.